U.S. pharma giant copyright scrapped two experimental weight loss drugs last 12 months—a at the time-every day tablet, lotiglipron, as a consequence of elevated liver enzymes as well as a 2 times-daily capsule, danuglipron, as a consequence of robust side effects—but CEO Albert Bourl